David Malcom Rodman
CIK 1672659 · Chief Medical Officer · last filed 2026-07-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.42M
Companies
2
Total Filings
106
Lifetime Open-Market Net
-$20.01M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MLYS | Chief Medical Officer | 51,800 | $27.33 | $1.42M | -$19.92M | 56 | 2026-07-20 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Exec Vice President and CMO | 2,842 | — | — | -$89.2K | 4 | 2017-01-05 |
Recent Filings · Page 6 of 11
106 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-09 | MLYS | Notice (144) | −2,170 | -$72.2K | EDGAR |
| 2026-01-06 | MLYS | Mixed | −10,031 | -$6.16M | EDGAR |
| 2026-01-02 | MLYS | Notice (144) | −262,752 | -$9.38M | EDGAR |
| 2025-10-15 | MLYS | Notice (144) | −10,369 | -$446.0K | EDGAR |
| 2025-10-15 | MLYS | Sell (S) | −10,369 | -$446.0K | EDGAR |
| 2025-09-16 | MLYS | Sell (S) | −11,367 | -$409.3K | EDGAR |
| 2025-09-15 | MLYS | Notice (144) | −11,367 | -$409.3K | EDGAR |
| 2025-08-14 | MLYS | Mixed | −5,016 | -$140.1K | EDGAR |
| 2025-08-13 | MLYS | Notice (144) | −11,365 | -$147.0K | EDGAR |
| 2025-07-15 | MLYS | Mixed | −5,017 | -$159.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.